miRNAs在三阴性乳腺癌多药耐药性中的研究进展  

Research progress of miRNAs in multidrug resistance of triple negative breast cancer

作　　者：邓榆薇 路丹[1] Deng Yuwei;Lu Dan(Department of Medical Oncology,the Second Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150081,China.)

机构地区：[1]哈尔滨医科大学附属第二医院肿瘤内科

出　　处：《现代肿瘤医学》2019年第23期4304-4307,共4页Journal of Modern Oncology

基　　金：吴阶平医学基金会临床科研专项资助基金(编号:320.6750.17182)

摘　　要：三阴性乳腺癌作为乳腺恶性肿瘤中最具侵袭性的类型,化学治疗是其主要而有效的治疗手段,但多药耐药性的产生仍是影响疗效的主要障碍。miRNAs是一种内生型的、非编码小RNAs,它作为一种潜在的致瘤因子或抑制因子,能靶向调节其目的基因从而参与肿瘤的耐药。因此,在开拓新的三阴性乳腺癌基因治疗的策略中,miRNAs具有潜在的治疗价值。本文总结了miRNAs在三阴性乳腺癌多药耐药中的作用机制及其在治疗中的应用前景。Triple-negative breast carcinoma(TNBC) is one of the most aggressive types of breast cancer.Chemotherapy is the main and effective treatment,however,the emergence of multidrug resistance is still the chief obstacle to curative effect.MicroRNAs are endogenously synthesized,small,non-coding RNAs,where they can act as potent oncogenes or tumor suppressors by targeting relative genes involving in cancer chemoresistance.MicroRNAs are,therefore,considered amongst the promising candidates for development of novel therapeutic approaches against TNBC.In this review,we summarized mechanism of action of microRNAs in multidrug resistance(MDR) and promising treatment perspective in TNBC.

关 键 词：三阴性乳腺癌 MIRNAS 多药耐药 基因干预 

分 类 号：R737.9[医药卫生—肿瘤]